MedTrace Logo

Predicting Neoadjuvant Therapy Response of Rectal Cancer With MRI

NCT02640586 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1614

Last updated 2023-06-22

No results posted yet for this study

Summary

The purpose of this study is to investigate if MRI scans performed after neoadjuvant radiotherapy can predict the therapeutic response of rectal cancer following preoperative chemo-radiotherapy. This will help doctors to better tailor treatments for rectal cancer in the future.

Conditions

  • Rectal Neoplasms

Interventions

DEVICE

three MR examination

Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.

Sponsors & Collaborators

  • Sun Ying-Shi

    lead OTHER

Principal Investigators

  • Ying-Shi Sun, MD · No.52 Fu Cheng Road, Hai Dian District, Beijing, 10142

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-10
Primary Completion
2020-07-17
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02640586 on ClinicalTrials.gov